Life on the Frontline
Life on the Frontline
HomeNotesChatPharmacology for Acute CareRecent UpdatesPulse Checks and Reflections !ABG SeriesArchiveAbout
Sign in
Pharmacology for Acute Care

Etomidate in the Emergency Department

Balancing hemodynamic stability with adrenal effects

Life on the Frontline's avatar
Life on the Frontline
Apr 1

Where etomidate fits in the ED ?

Etomidate is one of the most commonly used induction agents for:

  • Rapid Sequence Intubation (RSI)

  • Short procedural sedation (e.g., cardioversion)

Its appeal lies in:

  • Rapid onset (10–20 sec)

  • Short duration (4–10 min)

  • Minimal cardiovascular depression

This makes it particularly valuable in critically ill or hypotensive patients, where even small drops in blood pressure can be dangerous.


Dosing essentials

  • RSI: 0.3 mg/kg IV (max ~40 mg)

  • Unstable / elderly: 0.2 mg/kg

  • Procedural sedation: 0.1 mg/kg

Always dose using actual body weight to avoid awareness during paralysis.


Clinical advantages

  • Preserves hemodynamic stability better than most induction agents

  • Maintains cerebral perfusion pressure → useful in head injury

  • Reliable intubating conditions with high first-pass success

  • Rapid recovery profile for short procedures


Adrenal suppression: the central controversy

Mechanism

Etomidate inhibits 11β-hydroxylase, impairing cortisol synthesis:

  • Leads to reduced endogenous cortisol production

  • Effect occurs even after a single dose

Duration:

  • Suppression may last 6–72 hours


Biochemical vs clinical significance

  • Biochemical suppression:
    Almost universal → low cortisol levels after administration

  • Clinical adrenal insufficiency:
    Variable → may present as:

    • Persistent hypotension

    • Increased vasopressor requirement

Key point:
Not all patients with low cortisol develop clinically significant instability.


Adrenal effects in real-world ED practice

In the emergency setting, etomidate-induced adrenal suppression is best understood as a transient physiologic trade-off rather than a definitive clinical harm.

While cortisol levels drop predictably after a single dose, most patients do not manifest overt adrenal crisis.

The effect becomes clinically relevant primarily in septic shock, where endogenous cortisol is crucial for maintaining vascular tone and catecholamine responsiveness.

In such patients, etomidate may contribute to vasopressor dependence or delayed shock reversal, even though a clear increase in mortality has not been consistently demonstrated. In contrast, in undifferentiated shock or cardiogenic instability, the immediate hemodynamic stability provided during intubation often outweighs this transient endocrine effect, making etomidate a reasonable and frequently preferred choice.

What the evidence shows

General ED population

  • No consistent increase in mortality after single-dose use

  • Benefits in maintaining hemodynamics often outweigh risks

Sepsis and septic shock

  • Higher rates of adrenal suppression

  • Increased vasopressor requirement seen in several studies

  • No clear mortality difference compared with alternatives

Interpretation:

  • The signal is physiologic (pressor need) rather than definitively outcome-driven


Other important adverse effects

  • Myoclonus (~30%) → limits use in procedural sedation

  • No analgesia → must combine with appropriate agents

  • Transient apnea/hypoventilation possible

  • Injection site pain (~20%)

  • Avoid repeat dosing


Etomidate vs Ketamine: bedside decision-making

Outcomes between agents are largely similar—choice depends on physiology and context rather than superiority


Steroids after etomidate?

  • Routine steroid use is not recommended

  • No clear improvement in outcomes

  • Reserve steroids for established refractory septic shock, not prophylaxis


Practical ED approach

Use etomidate when:

  • Patient is hemodynamically unstable

  • Concern for peri-intubation hypotension

  • Need for neuroprotection

Consider alternatives when:

  • Septic shock with high vasopressor requirement

  • Concern for adrenal insufficiency impact


Take-home message

  • Etomidate provides rapid, reliable, hemodynamically stable induction

  • It causes predictable, transient adrenal suppression

  • Clinical impact is usually limited, but context matters in sepsis

  • The decision is not about the drug alone—it’s about the patient in front of you

“Etomidate protects the pressure upfront—just be mindful of the cortisol trade-off.”

Discussion about this post

User's avatar

Keep reading

Life on the Frontline

Inside one of India’s busiest EDs: evidence-based updates, difficult decisions, system failures, medical hierarchy, and the emotional realities of emergency medicine—shared directly from the front line.

  • About
  • Archive
  • Sitemap
© 2026 Dr Arihant Jain · Privacy ∙ Terms ∙ Collection notice
Start your SubstackGet the app
Substack is the home for writing, podcasting, and media founders.